中国卒中杂志 ›› 2019, Vol. 14 ›› Issue (05): 468-473.DOI: 10.3969/j.issn.1673-5765.2019.05.012
熊荣,黄光
收稿日期:
2019-02-22
出版日期:
2019-05-20
发布日期:
2019-05-20
通讯作者:
黄光 hsmmt@sina.com
Received:
2019-02-22
Online:
2019-05-20
Published:
2019-05-20
摘要:
主动脉瓣狭窄是老年人最常见瓣膜疾病,主动脉瓣置换术成功地降低了该病的死亡率并 极大提高了患者的生活质量。主动脉瓣膜置换术后卒中为其常见并发症,可能与手术操作、病变瓣膜 区凝血及抗凝血系统失衡等因素相关。有效的抗栓药物治疗及脑保护装置的使用可减少卒中的发生。 本文就主动脉瓣膜置换术相关卒中的发病率、发病机制及预防措施进行综述,旨在为临床治疗和预 防卒中提供帮助。
熊荣,黄光. 主动脉瓣膜置换术后卒中研究进展[J]. 中国卒中杂志, 2019, 14(05): 468-473.
XIONG Rong, HUANG Guang. Advance in Stroke after Aortic Valve Replacement[J]. Chinese Journal of Stroke, 2019, 14(05): 468-473.
[1] NKOMO V T,GARDIN J M,SKELTON T N,etal. Burden of valvular heart diseases:a populationbasedstudy[J]. Lancet,2006,368(9540):1005-1011.[2] BACH D S,SIAO D,GIRARD S E,et al.Evaluation of patients with severe symptomaticaortic stenosis who do not undergo aortic valvereplacement:the potential role of subjectivelyoverestimated operativerisk[J]. Circ Cardiovasc QualOutcomes,2009,2(6):533-539.[3] CRIBIER A,ELTCHANINOFF H,BASH A,et al.Percutaneous transcatheter implantation of an aorticvalve prosthesis for calcific aortic stenosis:firsthuman case description[J]. Circulation,2002,106(24):3006-3008.[4] MESSÉS R,ACKER M A,KASNER S E,et al.Stroke after aortic valve surgery:results from aprospective cohort[J]. Circulation,2014,129(22):2253-2261.[5] O’BRIEN S M,SHAHIAN D M,FILARDOG,et al. The Society of Thoracic Surgeons 2008cardiac surgery risk models:part 2--isolated valvesurgery[J/OL]. Ann Thorac Surg,2009,88(1Suppl):23-42. https://linkinghub.elsevier.com/retrieve/pii/S0003497509010595. DOI:10.1016/j.athoracsur.2009.05.056.[6] HAMM C W,MOLLMANN H,HOLZHEY D,etal. The German Aortic Valve Registry(GARY):inhospitaloutcome[J]. Eur Heart J,2014,35(24):1588-1598.[7] ElBARDISSI A W,SHEKAR P,COUPER G S,etal. Minimally invasive aortic valve replacement inoctogenarian,high-risk,transcatheter aortic valveimplantation candidates[J]. J Thorac CardiovascSurg,2011,141(2):328-335.[8] THOURANI V H,AILAWADI G,SZETO W Y,etal. Outcomes of surgical aortic valve replacement inhigh-risk patients:a multiinstitutional study[J]. AnnThorac Surg,2011,91(1):49-55.[9] LIKOSKY D S,SORENSEN M J,DACEY L J,et al. Long-term survival of the very elderly undergoingaortic valve surgery[J/OL]. Circulation,2009,120(11 Suppl):127-133. https://doi.org/10.1161/CIRCULATIONAHA.108.842641.[10] SMITH C R,LEON M B,MACK M J,etal. Transcatheter versus surgical aortic-valvereplacement in high-risk patients[J]. N Engl J Med,2011,364(23):2187-2198.[11] MACK M J,LEON M B,SMITH C R,et al. 5-Yearoutcomes of transcatheter aortic valve replacementor surgicalaortic valve replacement for high surgicalrisk patients with aortic stenosis(PARTNER 1):arandomised controlled trial[J]. Lancet,2015,385(9986):2477-2484.[12] THOMAS M,SCHYMIK G,WALTHER T,etal. One-year outcomes of cohort 1 in the EdwardsSAPIEN Aortic Bioprosthesis European Outcome(SOURCE)registry:the European registry oftranscatheter aortic valve implantation using theEdwards SAPIEN valve[J]. Circulation,2011,124(4):425-433.[13] MACK M J,BRENNAN J M,BRINDIS R,etal. Outcomes following transcatheter aortic valvereplacement in the United States[J]. JAMA,2013,310(19):2069-2077.[14] GILARD M,ELTCHANINOFF H,IUNG B,et al.Registry of transcatheter aortic-valve implantation inhigh-risk patients[J]. N Engl J Med,2012,366(18):1705-1715.[15] MOAT N E,LUDMAN P,DE BELDER M A,etal. Long-term outcomes after transcatheter aorticvalve implantation in high-risk patients with severeaortic stenosis:the U. K. TAVI(United KingdomTranscatheter Aortic Valve Implantation)Registry[J].J Am Coll Cardiol,2011,58(20):2130-2138.[16] ZHAO Q M,LOGNONE T,lVASCAU C,etal. Procedural results and 30-day clinical eventsanalysis following Edwards transcatheter aorticvalve implantation in 48 consecutive patients:initialexperience[J]. Clin Med J(Engl),2012,125(16):2807-2810.[17] HE W,HUANG R R,SHI Q Y,et al.Bispectralindex-guided sedation in transfemoral transcatheteraortic valve implantation:a retrospective controlstudy [J]. J Zhejiang Univ-Sci B(Biomed &Biotechnol),2017,18(4):353-359.[18] IOANNIS M,MIKKEL M S,GEORGE D D,et al.Stroke After Transcatheter Aortic Valve Replacement:Incidence,Risk Factors,Prognosis,and PreventiveStrategies[J]. Clin Cardiol,2014,37(12):756-764.[19] JAKOBSEN L,TERKELSEN C J,SØNDERGAARD L,et al. Short- and long-termmortality and stroke risk after transcatheter aorticvalve implantation[J]. Am J Cardiol,2018,121(1):78-85.[20] TAY E L,GURVITCH R,WIJESINGHE N,et al.A high-risk periodfor cerebrovascular events existsafter transcatheter aortic valve implantation[J].JACC Cardiovasc Interv,2011,4(12):1290-1297.[21] MILLER D C,BLACKSTONE E H,MACK M J,et al. Transcatheter(TAVR)versus surgical(AVR)aortic valve replacement:occurrence,hazard,riskfactors,and consequences of neurologic events inthe PARTNER trial[J]. J Thorac Cardiovasc Surg,2012,14(3):832-843.[22] ADAMS D H,POPMA J J,REARDON M J.Transcatheter aortic-valve replacement with a selfexpandingprosthesis[J]. N Engl J Med,2014,371(10):967-968.[23] KAHLERT P,KNIPP S C,SCHLAMANN M,etal. Silent and apparent cerebral ischemia afterpercutaneous transfemoral aortic valve implantation:a diffusion-weighted magnetic resonance imagingstudy[J]. Circulation,2010,121(7):870-878.[24] STORTECKY S,WINDECKER S. Stroke:aninfrequent but devastating complication incardiovascular interventions[J]. Circulation,2012,126(25):2921-2924.[25] ALASSAR A,ROY D,VALENCIA O,et al.Cerebral Embolization during transcatheter aorticvalve implantation compared with surgical aorticvalve replacement[J/OL]. Interact Cardio VascThorac Surg,2013,17(2):S134-S135. https://doi.org/10.1093/icvts/ivt372.268.[26] VAN DER LINDEN J,CASIMIR-AHN H. When docerebral emboli appear during open heart operations?A transcranial Doppler study[J]. Ann Thorac Surg,1991,51(2):237-241.[27] VAN MIEGHEM N M,SCHIPPER M E,LADICHE,et al. Histopathology of embolic debris capturedduring transcatheter aortic valve replacement[J].Circulation,2013,127(22):2194-2201.[28] HYNES B G,ROD ES-CABAU J. Transcatheteraortic valve implantation and cerebrovascular events:the current state of the art[J/OL]. Ann N Y Acad Sci,2012,1254:151-163. https://doi.org/10.1111/j.1749-6632.2012.06477.x.[29] MARECHAUX S,CORSEAUX D,VINCENTELLIA,et al. Identification of tissue factor inexperimental aortic valve sclerosis[J]. CardiovascPathol,2009,18(2):67-76.[30] NOMBELA-FRANCO L,WEBB J G,DE JAEGERE P P,et al. Timing,predictive factors,andprognostic value of cerebrovascular eventsin a largecohort of patients undergoing transcatheter aorticvalve implantation[J]. Circulation,2012,126(25):3041-3053.[31] WOLF P A,D’AGOSTINO R B,BELANGER AJ,et al. Probability of stroke:a risk profile from theFramingham Study[J]. Stroke,1991,22(3):312-318.[32] NISHIMURA R A,OTTO C M,BONOW R O,etal. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients withvalvular heart disease:a report of the AmericanCollege of Cardiology/American Heart AssociationTask Force on Clinical Practice Guidelines[J]. J AmColl Cardiol,2017,70(2):252-289.[33] WHITLOCK R P,SUN J C,FREMES S E,et al.Antithrombotic and thrombolytic therapy for valvulardisease:Antithrombotic Therapy and Preventionof Thrombosis,9th ed:American College ofChest Physicians Evidence-Based Clinical PracticeGuidelines[J/OL]. Chest,2012,141(2 Suppl):576-600. https://linkinghub.elsevier.com/retrieve/pii/S0012369212601329. DOI:10.1378/chest.11-2305.[34] TURPIE A G,GENT M,LAUPACIS A,et al. Acomparison of aspirin with placebo in patients treatedwith warfarin after heart-valve replacement[J]. N EnglJ Med,1993,329(8):524-529.[35] EIKELBOOM J W,CONNOLLY S J,BRUECKMANN M,et al. RE-ALIGN Investigators.Dabigatran versus warfarin in patients withmechanical heart valves[J]. N Engl J Med,2013,369(13):1206-1214.[36] RIAZ H,ALANSARI S A,KHAN M S,et al.Safety and use of anticoagulation after aortic valvereplacement with bioprostheses:a meta-analysis[J].Circ Cardiovasc Qual Outcomes,2016,9(3):294-302.[37] BOLOTIN G,HUBER C H,SHANI L,et al. Novelemboli protection system during cardiac surgery[J].Ann Thorac Surg,2014,98(5):1627-1633.[38] MACK M J,ACKER M A,GELIJNS A C,et al.Effect of cerebral embolic protection devices onCNS infarction in surgical aortic valve replacementa randomized clinical trial[J]. JAMA,2017,318(6):536-547.[39] USSIA G P,SCARABELLI M,MULE M,etal. Dual antiplatelet therapy versus aspirin alonein patients undergoing transcatheter aortic valveimplantation[J]. Am J Cardiol,2011,108(12):1772-1776.[40] DURAND E,BLANCHARD D,CHASSAINGS,et al. Comparison of two antiplatelet therapystrategies in patients undergoing transcatheter aorticvalve implantation[J]. Am J Cardiol,2014,113(2):355-360.[41] OTTO C M,DHARAM J K,KAREN P,et al.2017 ACC expert consensus decision pathwayfor transcatheter aortic valve replacement in themanagement of adults with aortic stenosis:a reportof the American College of Cardiology Task Forceon Clinical Expert Consensus Documents[J]. J AmColl Cardiol,2017,69(10):1313-1346.[42] CHAKRAVARTY T,SøNDERGAARD L,FRIEDMAN J,et al. Subclinical leaflet thrombosisin surgical and transcatheter bioprosthetic aorticvalves:an observational study[J]. The Lancet,2017,389(10087):2383-2392.[43] MAKKAR R R,FONTANA G,JILAIHAWIH,et al. Possible subclinical leaflet thrombosis inbioprosthetic aortic valves[J]. N Engl J Med,2015,373(16):2015-2024.[44] MERIE C,KOBER L,SKOVOLSEN P,et al.Association of warfarin therapy duration afterbioprosthetic aortic valve replacement with riskof mortality,thromboembolic complications,andbleeding[J]. JAMA,2012,308(20):2118-2125.[45] KALICH B A,ALLENDER J E,HOLLIS I B.Medication Management of Patients UndergoingTranscatheter Aortic Valve Replacement[J].Pharmacotherapy,2018,38(1):122-138.[46] VAN MIEGHEM N M,TCHETCHE D,CHIEFFOA,et al. Incidence,predictors,and implicationsof access site complications with transfemoraltranscatheter aortic valve implantation[J]. Am JCardiol,2012,110(9):1361-1367.[47] GHANEM A,KOCUREK J,SINNING J M,et al.Novel approaches for prevention of stroke related totranscatheter aortic valve implantation[J]. ExpertRev Cardiovasc Ther,2013,11(10):1311-1320.[48] ABDUL-JAWAD ALTISENT O,PURI R,RODESCABEAUJ. Embolic protection devices during TAVI:current evidence and uncertainties[J]. Rev EspCardiol(Engl Ed),2016,69(10):962-972. |
[1] | 鲁燕, 杨保荣, 黄向萍, 杨冠桂, 陈圣文, 李建荣, 曾小明. 县级医院急性缺血性卒中超时间窗经MRI筛选溶栓的病例对照研究 [J]. 中国卒中杂志, 2022, 17(12): 1321-1326. |
[2] | 楚悦琪, 周凯云, 王田燕, 王炯彬, 李真. 卒中后吞咽障碍应用耳穴压豆治疗效果的meta分析 [J]. 中国卒中杂志, 2022, 17(12): 1327-1334. |
[3] | 周甜甜, 苏文杰, 连松勇, 林友聪. 丰富环境对卒中后血管性痴呆患者认知功能的影响 [J]. 中国卒中杂志, 2022, 17(12): 1343-1349. |
[4] | 吴娱倩, 张玉梅, 范小伟, 王安心, 逄文斌. 运动想象-动觉治疗对缺血性卒中患者手功能康复效果的研究[J]. 中国卒中杂志, 2022, 17(12): 1366-1371. |
[5] | 蒋林, 李靖. 基于知识图谱分析人工智能用于卒中研究的现状及趋势 [J]. 中国卒中杂志, 2022, 17(12): 1372-1380. |
[6] | 梁潇, 钱海兵. 水通道蛋白4与卒中后认知障碍的关系研究进展[J]. 中国卒中杂志, 2022, 17(12): 1385-1390. |
[7] | 吴晓莉, 刘丽旭. 肥胖对卒中预后的影响[J]. 中国卒中杂志, 2022, 17(12): 1391-1395. |
[8] | 伊珞, 周宏宇, 仇鑫, 李子孝, 王拥军. 动脉粥样硬化性疾病的DNA甲基化改变[J]. 中国卒中杂志, 2022, 17(11): 1163-1170. |
[9] | 王誉博, 李子孝, 王拥军. 表观遗传学与缺血性卒中后氧化应激的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1171-1177. |
[10] | 闫然, 闵妍, 全柯华, 李子孝. 脑源性神经营养因子和血清素再摄取转运体编码基因甲基化与卒中预后的关系[J]. 中国卒中杂志, 2022, 17(11): 1178-1182. |
[11] | 崔凌云, 仇鑫, 周宏宇, 李子孝, 王拥军. DNA甲基化与2型糖尿病的相关性研究进展[J]. 中国卒中杂志, 2022, 17(11): 1183-1188. |
[12] | 邓宇含, 刘爽, 王子尧, 汪雨欣, 刘宝花. 基于结构化数据和机器学习模型预测普通人群卒中发病风险的系统评价和meta分析 [J]. 中国卒中杂志, 2022, 17(11): 1189-1197. |
[13] | 刘光亮, 韩凯月, 苏文龙, 张皓. 不同强度有氧踏车训练对不同病程缺血性卒中患者运动和心肺适能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1203-1208. |
[14] | 孙默一, 张玉梅, 刘然, 赵依双. 不同时间康复介入对卒中患者运动功能的影响 [J]. 中国卒中杂志, 2022, 17(11): 1209-1215. |
[15] | 胡红梅, 杨磊, 于玲, 秦伟, 白明悦, 胡文立. 急性单发小脑小梗死的临床特征 [J]. 中国卒中杂志, 2022, 17(11): 1221-1226. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||